Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
Sarcoidosis is a systemic granulomatous disease of unknown etiology, in which the lungs and intrathoracic lymph nodes are predominant sites of involvement. Pulmonary hypertension is a known complication of sarcoidosis. Treatment of sarcoidosis-associated pulmonary hypertension has traditionally focused on the initiation of systemic corticosteroids, but has had inconsistent results. We present a patient with sarcoidosis-associated pulmonary hypertension who achieved substantial clinical improvement with the dual endothelin receptor antagonist bosentan.
Foley
Raymond J
RJ
Division of Pulmonary/Critical Care Medicine, University of Connecticut School of Medicine, Farmington, Conn., USA. rfoley@uchc.edu
Metersky
Mark L
ML
D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077300:Bosentan; D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D017565:Sarcoidosis, Pulmonary / Q000150:complications*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D019332:Endothelin-1; D013449:Sulfonamides; D000077300:Bosentan